JP2024533848A5 - - Google Patents
Info
- Publication number
- JP2024533848A5 JP2024533848A5 JP2024520962A JP2024520962A JP2024533848A5 JP 2024533848 A5 JP2024533848 A5 JP 2024533848A5 JP 2024520962 A JP2024520962 A JP 2024520962A JP 2024520962 A JP2024520962 A JP 2024520962A JP 2024533848 A5 JP2024533848 A5 JP 2024533848A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- c4bpβ
- antibody
- amino acid
- chimeric construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306399 | 2021-10-06 | ||
| EP21306399.3 | 2021-10-06 | ||
| PCT/EP2022/077847 WO2023057588A1 (en) | 2021-10-06 | 2022-10-06 | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533848A JP2024533848A (ja) | 2024-09-12 |
| JP2024533848A5 true JP2024533848A5 (cg-RX-API-DMAC7.html) | 2025-10-20 |
Family
ID=78463430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520962A Pending JP2024533848A (ja) | 2021-10-06 | 2022-10-06 | 炎症組織へのターゲティング特異性を備えるインターロイキン２キメラコンストラクト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240376172A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412631A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024533848A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240113459A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118414160A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022360645A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233644A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311883A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004291A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023057588A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202402730B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024194686A2 (en) * | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2024194685A2 (en) * | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2026159300A1 (en) | 2025-01-24 | 2026-07-30 | Iltoo Pharma | M3c65 antibody and derivatives thereof for targeting inflammation |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341562C (en) | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
| FI82266C (fi) | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| FR2869323B1 (fr) | 2004-04-22 | 2006-07-21 | Univ Reims Champagne Ardenne | Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| US8437577B2 (en) | 2009-03-05 | 2013-05-07 | Tektronix, Inc. | Methods and systems for image registration |
| WO2011160845A2 (en) * | 2010-06-24 | 2011-12-29 | Medirista Biotechnologies Ab | Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| PT3102595T (pt) * | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| KR102493543B1 (ko) | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| ES2982752T3 (es) | 2015-10-22 | 2024-10-17 | Iltoo Pharma | Composiciones farmacéuticas de il-2 |
| WO2019148204A1 (en) * | 2018-01-29 | 2019-08-01 | The Regents Of The University Of California | Therapies and methods to treat tlr2-mediated diseases and disorders |
| WO2020252421A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
| US20230036793A1 (en) * | 2019-12-12 | 2023-02-02 | Iltoo Pharma | Interleukin 2 chimeric constructs |
-
2022
- 2022-10-06 CN CN202280067635.6A patent/CN118414160A/zh active Pending
- 2022-10-06 MX MX2024004291A patent/MX2024004291A/es unknown
- 2022-10-06 EP EP22801746.3A patent/EP4412631A1/en active Pending
- 2022-10-06 JP JP2024520962A patent/JP2024533848A/ja active Pending
- 2022-10-06 KR KR1020247013994A patent/KR20240113459A/ko active Pending
- 2022-10-06 AU AU2022360645A patent/AU2022360645A1/en active Pending
- 2022-10-06 US US18/698,994 patent/US20240376172A1/en active Pending
- 2022-10-06 IL IL311883A patent/IL311883A/en unknown
- 2022-10-06 WO PCT/EP2022/077847 patent/WO2023057588A1/en not_active Ceased
- 2022-10-06 CA CA3233644A patent/CA3233644A1/en active Pending
-
2024
- 2024-04-09 ZA ZA2024/02730A patent/ZA202402730B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6694409B2 (ja) | Ｔｎｆｓｆ一本鎖分子 | |
| JP6181145B2 (ja) | 改善された特異性を有する新規免疫グロブリン結合タンパク質 | |
| JP7323949B2 (ja) | フラジェリン融合タンパク質及びその使用 | |
| EP3998077B1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| Mertens | Tribodies: fab–scfv fusion proteins as a platform to create multifunctional pharmaceuticals | |
| CN103987728B (zh) | 抗癌融合蛋白 | |
| JP2023504914A5 (cg-RX-API-DMAC7.html) | ||
| CN107108737B (zh) | c-met特异性人抗体及其制备方法 | |
| FI3368555T3 (fi) | Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus | |
| JP2023553697A5 (cg-RX-API-DMAC7.html) | ||
| CN105473609A (zh) | 用于表达肽和蛋白的方法 | |
| EP3344647B1 (en) | Coiled-coil connector | |
| CN106380517B (zh) | 一种对中东呼吸综合征冠状病毒具有中和活性的小分子抗体及其应用 | |
| JP2009507503A5 (cg-RX-API-DMAC7.html) | ||
| Eisenmesser et al. | Expression, purification, refolding, and characterization of recombinant human interleukin-13: utilization of intracellular processing | |
| CN120590542A (zh) | 基于clec9a的嵌合蛋白复合物 | |
| CN103562220A (zh) | 抗癌融合蛋白 | |
| Orrapin et al. | Recombinant expression of novel protegrin-1 dimer and LL-37-linker–histatin-5 hybrid peptide mediated biotin carboxyl carrier protein fusion partner | |
| KR20190109947A (ko) | 재조합 인간 혈청 알부민의 수용성 과발현 및 정제 방법 | |
| CN100427506C (zh) | 从融合多肽制备感兴趣的多肽的方法 | |
| CN101265291A (zh) | 一种重组猪源抗菌肽pg4及其生物合成方法与应用 | |
| JP2023550191A5 (cg-RX-API-DMAC7.html) | ||
| JP2025036661A (ja) | 抗体酵素の革新的製造技術 | |
| WO2023078436A1 (en) | Fusion proteins comprising 072 core peptide and use thereof | |
| US8470971B2 (en) | Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient |